Global Market Dynamics
Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are expected to drive the growth of the In situ Hybridization Market in the coming years.
By application, the in situ hybridization market is categorized into cancer diagnosis, cytology, neuroscience, immunology and infectious diseases. The cancer diagnosis segment is expected to command the largest share of the global in situ hybridization market, by application in 2016.
This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This is attributed to factors such as rising prevalence of cancer, increasing adoption of FISH in diagnosis of cancer, and rising demand for FISH-based companion diagnostics for cancer.
On the basis of end users, the global in situ hybridization market is segmented into molecular diagnostic laboratories, academic & research institutes, contract research organizations, and pharmaceutical & biotechnology companies. In 2016, the molecular diagnostic laboratories segment is estimated to account for the largest share of the global in situ hybridization market, by end user.
This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This can be attributed to the availability of specialized skill sets in molecular diagnostic laboratories for ISH technique, rising prevalence of cancer coupled with genetic abnormalities, and increasing adoption of FISH in diagnosis of cancer and genetic abnormalities.
Looking Out for More Details | Download the PDF Brochure
Industry’s Revenue Growth Expectations:
This report studies the global in situ hybridization market for the forecast period of 2016 to 2021. This market is expected to reach USD 739.9 Million by 2021 from USD 557.1 Million in 2016, growing at a CAGR of 5.8%.
Geographical Growth Scenario:
In the coming years, the market is expected to witness the highest growth in the Asia-Pacific region. This can be attributed to the growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the in situ hybridization market in this region.
North America is expected to account for the largest share of the global market. This can be attributed to growing clinical and research in cancer by biotechnology and pharmaceutical companies, government initiatives, increasing prevalence and diagnosis of cancer in the U.S. and Canada, and increasing adoption of companion diagnostics. Increased adoption of Companion Diagnostics is attributed to the development and launch of newer therapeutic agents.
In the U.S., the in situ hybridization market is driven by increasing government initiatives, growing biomedical research, rising prevalence of cancer, and growing demand for companion diagnostics and personalized medicine. In Canada, the growth of the market is driven by increased government funding and growing prevalence of cancer.
Leading Market Players:
Abbott Laboratories, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), and Bio SB Inc. (U.S.) are some of the key players in the in situ hybridization market worldwide.
The key strategies adopted by the major players include new product development, mergers & acquisitions, expansion, partnerships, agreements, and collaborations with other players in the in-situ hybridization landscape to meet the demand of their end users.
Stakeholders of the Global Market:
# Medical Device Manufacturers
# Diagnostic Laboratories
# Contract Research Organizations (CROs)
# Life Sciences Companies (Pharmaceutical/Biotechnology)
# Academic Institutes
# Government and Private Research Institutes
# Regulatory Bodies
# Market Research and Consulting Firms
# Venture Capitalists